The most widely used ICBs are the first-generation immune checkpoint inhibitors targeting PD-1 and PD-L1 (7), which can block tumor-related downregulation of the immune system to enhance antitumor immunity and offer a broad anticancer spectrum (8, 9). Here, CD274 is linked to neoplasm.